Changes in general practitioners' attitudes toward COVID-19 vaccination after first interim results: a longitudinal approach in France.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
03 10 2021
Historique:
pubmed: 14 7 2021
medline: 16 9 2021
entrez: 13 7 2021
Statut: ppublish

Résumé

We assessed whether the a priori acceptance by French general practitioners (GPs) of COVID-19 vaccines changed after the announcements about them in November 2020. In all, between two surveys in October-November and in November-December 2020, acceptance of COVID-19 vaccines increased among 16.9% of GPs and decreased among 23.0%. Among those with high acceptance in October-November (52.5%), 11.6% became hesitant-reluctant in November-December; in those with initial hesitancy-reluctance (24.6%), 15.2% showed high acceptance. Deteriorating acceptance was significantly associated with GPs' distrust in the Ministry of Health and a priori concerns about the safety of vaccines developed during an epidemic; the reverse was found for improving acceptance. In addition, better acceptance was more likely among GPs who perceived the medical severity of COVID-19 to be high and was less common among women. During a severe pandemic, GPs' trust in health institutions and perception of safety issues remain important predictors of their attitudes toward new vaccines. Vigilance is needed regarding health professionals' reactions to events that may cast doubt on the safety or efficacy of certain COVID-19 vaccines. Personalized approaches should be considered and tested to address their concerns as the situation and knowledge evolve.

Identifiants

pubmed: 34254880
doi: 10.1080/21645515.2021.1943990
pmc: PMC8437498
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3408-3412

Références

Int J Qual Stud Health Well-being. 2020 Dec;15(1):1757336
pubmed: 32400299
EBioMedicine. 2015 Jun 23;2(8):891-7
pubmed: 26425696
Vaccines (Basel). 2020 Dec 30;9(1):
pubmed: 33396832
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478623
Vaccine. 2010 Mar 24;28(15):2743-8
pubmed: 20117271
Vaccine. 2014 Apr 25;32(20):2281-7
pubmed: 24631097
Healthcare (Basel). 2020 Dec 03;8(4):
pubmed: 33287260
Acta Inform Med. 2020 Dec;28(4):241-247
pubmed: 33627924
Lancet Public Health. 2021 Apr;6(4):e195-e196
pubmed: 33556329
Soc Sci Med. 2020 Nov;265:113414
pubmed: 33038683
BMC Fam Pract. 2021 Feb 14;22(1):36
pubmed: 33583410
J Hosp Infect. 2021 Feb;108:168-173
pubmed: 33259883

Auteurs

Pierre Verger (P)

Faculty of Medicine, ORS PACA (Southeastern Health Regional Observatory), Marseille, France.

Dimitri Scronias (D)

Faculty of Medicine, ORS PACA (Southeastern Health Regional Observatory), Marseille, France.
Centre d'investigation Clinique de l'Hôpital Cochin-Pasteur (CIC 1417), Assistance Publique des Hôpitaux de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH